Q-omics provides the consensus-scored LLPHP3 profile across patient tissues and cancer cell-line models. LLPHP3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LLPHP3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, LLPHP3 RNA expression shows 12,070 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UCEC, and HNSC as cancer lineages where LLPHP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LLPHP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LLPHP3 survival associations across molecular data types. LLPHP3 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LLPHP3 RNA expression–survival associations across cancer types. High LLPHP3 expression shows unfavorable associations in UCEC, KIRP, LGG and ACC, but favorable associations in THCA and UCS. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LLPHP3 RNA expression.
This table summarizes LLPHP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LLPHP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LLPHP3 shows higher tumor expression in HNSC, COAD, BRCA, LUSC, KIRP and CHOL. The HNSC box plot shows higher LLPHP3 RNA expression in tumor versus normal tissue (log2 FC = +0.490, t-test p < 0.001).
This table shows molecular features associated with LLPHP3 in patient tissues and cancer cell lines. In patient samples, LLPHP3 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
